A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
about
Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesRapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesMultifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variantsIs dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeSwitch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders.Recurrent myelitis in common variable immunodeficiency successfully managed with high-dose subcutaneous immunoglobulin.Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryBringing immunoglobulin knowledge up to date: how should we treat today?Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.Multifocal motor neuropathy: current therapies and novel strategies.Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.Subcutaneous IgG in neurologic diseases.Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.Outcome measures in MMN revisited: further improvement needed.New Frontiers in Subcutaneous Immunoglobulin Treatment.Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins.Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study.A comparison between intravenous and subcutmaneous immunogobulin.Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy.Adverse Effects of Immunoglobulin Therapy.
P2860
Q26745685-80A2352D-01D9-470E-801B-A3D2E45F8794Q26864907-5CBEEE83-BCC4-4D73-8BBF-9B1D622168D2Q28390264-056FB4C3-4BAA-49E5-8952-A6DA4FEC4F87Q33419638-A19C1EB5-760B-4680-A217-A3F797B07112Q34457953-ABC11341-58C6-4427-9AD7-8805D7945B7BQ35780802-9857CEDE-D665-4EB3-ADF7-C81C81E70158Q35975877-986ECEFC-B907-46A6-B3AC-E682A44FDD98Q36094658-9C819069-4D9B-4365-B7C7-32677AA79844Q36737563-FCE1BC1C-8E84-4EDA-B448-55E14BF98F80Q37901520-BA8CD7C8-8DCA-482D-90A6-BCFE956DEF43Q37959252-617F5A6B-98D7-4A29-91D1-7735B31E5342Q38091664-F21D0CFE-2013-4B1A-8475-2A98C66BF473Q38152428-3B561EFE-567B-46CD-B034-E7EC20F703C4Q38171572-E8C8BA7E-4C6F-4DC3-85D5-0A5985CC369FQ38270717-3BE2BCB5-CE16-4411-8E65-FDEBA37CE4AEQ39370917-D4B97263-3183-40EA-8CC0-10FB2200C961Q39604919-CAC71CAA-34FC-4D96-BECF-E2A92A5B48A2Q40793045-C99599C3-37A8-4171-9B63-04E411131BB6Q42775420-623B5C11-0152-456A-891E-A14C148BC876Q43961509-550B14B9-E6CB-4BF3-91FA-E53FA8A46ABCQ44954147-1C0BF9D8-AEEB-4858-8705-AFB73B1D2927Q48437188-E2ED14DC-7E29-445B-B7AF-244B82A709AEQ51134410-37D3392C-2906-4ADD-95B0-5373D23C8E85Q55465940-9134E52C-F2E0-4525-BAC5-13A15CEA8D96
P2860
A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A smooth transition protocol f ...... -label proof-of-concept study.
@en
A smooth transition protocol f ...... -label proof-of-concept study.
@nl
type
label
A smooth transition protocol f ...... -label proof-of-concept study.
@en
A smooth transition protocol f ...... -label proof-of-concept study.
@nl
prefLabel
A smooth transition protocol f ...... -label proof-of-concept study.
@en
A smooth transition protocol f ...... -label proof-of-concept study.
@nl
P2093
P2860
P1476
A smooth transition protocol f ...... -label proof-of-concept study.
@en
P2093
Andreas Baumann
Dirk S Schmidt
Janet Burton
Matthias Sturzenegger
Patrizia Dacci
Raffaella Fazio
Siraj A Misbah
P2860
P356
10.1111/J.1529-8027.2011.00330.X
P577
2011-06-01T00:00:00Z